Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Christopher L Morton

Showing results (81-90 of 100) with videos related to

Pageof 10
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 17, 2008
Molecular characterization of the pediatric preclinical testing panelGeoffrey Neale, Xiaoping Su, Christopher L Morton, et al.
Pediatric Blood & Cancer|May 7, 2011
Testing of the topoisomerase 1 inhibitor Genz-644282 by the pediatric preclinical testing programPeter J Houghton, Richard Lock, Hernan Carol, et al.
Pediatric Blood & Cancer|September 17, 2013
Initial testing (stage 1) of the histone deacetylase inhibitor, quisinostat (JNJ-26481585), by the Pediatric Preclinical Testing ProgramHernan Carol, Richard Gorlick, E Anders Kolb, et al.
Scientific Reports|August 27, 2024
Whole genome and reverse protein phase array landscapes of patient derived osteosarcoma xenograft modelsChia-Chin Wu, Licai Huang, Zhongting Zhang, et al.
Molecular Therapy. Advances|May 15, 2026
Rational engineering of the P5 TRS-mimic site and REP78/68 start codon yields promoter variants that improve rAAV purity while maintaining high titersStephen M Winston, Mark A Brimble, Kristin B Wiggins, et al.
Blood|December 3, 2011
AAV-mediated gene transfer in the perinatal period results in expression of FVII at levels that protect against fatal spontaneous hemorrhageChristopher Binny, Jenny McIntosh, Marco Della Peruta, et al.
Cancer Chemotherapy and Pharmacology|March 31, 2011
Efficacy and pharmacokinetic/pharmacodynamic evaluation of the Aurora kinase A inhibitor MLN8237 against preclinical models of pediatric cancerHernan Carol, Ingrid Boehm, C Patrick Reynolds, et al.
Cancers|April 12, 2022
<i>TERT</i> Expression in Wilms Tumor Is Regulated by Promoter Mutation or Hypermethylation, WT1, and N-MYCCarolyn M Jablonowski, Hyea Jin Gil, Emilia M Pinto, et al.
Pediatric Blood & Cancer|October 27, 2006
The pediatric preclinical testing program: description of models and early testing resultsPeter J Houghton, Christopher L Morton, Chandra Tucker, et al.
Biorxiv : the Preprint Server for Biology|April 8, 2024
RBM39 degrader invigorates natural killer cells to eradicate neuroblastoma despite cancer cell plasticityShivendra Singh, Jie Fang, Hongjian Jin, et al.
Pageof 10

Showing results (81-90 of 100) with videos related to

Sort By:
Pageof 10
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 17, 2008
Molecular characterization of the pediatric preclinical testing panelGeoffrey Neale, Xiaoping Su, Christopher L Morton, et al.
Pediatric Blood & Cancer|May 7, 2011
Testing of the topoisomerase 1 inhibitor Genz-644282 by the pediatric preclinical testing programPeter J Houghton, Richard Lock, Hernan Carol, et al.
Pediatric Blood & Cancer|September 17, 2013
Initial testing (stage 1) of the histone deacetylase inhibitor, quisinostat (JNJ-26481585), by the Pediatric Preclinical Testing ProgramHernan Carol, Richard Gorlick, E Anders Kolb, et al.
Scientific Reports|August 27, 2024
Whole genome and reverse protein phase array landscapes of patient derived osteosarcoma xenograft modelsChia-Chin Wu, Licai Huang, Zhongting Zhang, et al.
Molecular Therapy. Advances|May 15, 2026
Rational engineering of the P5 TRS-mimic site and REP78/68 start codon yields promoter variants that improve rAAV purity while maintaining high titersStephen M Winston, Mark A Brimble, Kristin B Wiggins, et al.
Blood|December 3, 2011
AAV-mediated gene transfer in the perinatal period results in expression of FVII at levels that protect against fatal spontaneous hemorrhageChristopher Binny, Jenny McIntosh, Marco Della Peruta, et al.
Cancer Chemotherapy and Pharmacology|March 31, 2011
Efficacy and pharmacokinetic/pharmacodynamic evaluation of the Aurora kinase A inhibitor MLN8237 against preclinical models of pediatric cancerHernan Carol, Ingrid Boehm, C Patrick Reynolds, et al.
Cancers|April 12, 2022
<i>TERT</i> Expression in Wilms Tumor Is Regulated by Promoter Mutation or Hypermethylation, WT1, and N-MYCCarolyn M Jablonowski, Hyea Jin Gil, Emilia M Pinto, et al.
Pediatric Blood & Cancer|October 27, 2006
The pediatric preclinical testing program: description of models and early testing resultsPeter J Houghton, Christopher L Morton, Chandra Tucker, et al.
Biorxiv : the Preprint Server for Biology|April 8, 2024
RBM39 degrader invigorates natural killer cells to eradicate neuroblastoma despite cancer cell plasticityShivendra Singh, Jie Fang, Hongjian Jin, et al.
Pageof 10